Acute Myeloid Leukemia Therapeutics Market Forecast to 2020

1
Acute Myeloid Leukemia Therapeutics Market to
2020 - Novel Therapies to Offer Clinical Benefit
in Small Patient Cohorts
No. Pages 163
Published on September - 2014
2
.
Report Overview
About Acute Myeloid Leukemia Therapeutics Market
to 2020 - Novel Therapies to Offer Clinical
Benefit in Small Patient Cohorts Research Beam
added a report Acute Myeloid Leukemia
Therapeutics Market to 2020 - Novel Therapies to
Offer Clinical Benefit in Small Patient Cohorts.
Summary GBI Research, has released its latest
pharma report, "Acute Myeloid Leukemia
Therapeutics Market to 2020 - Novel Therapies to
Offer Clinical Benefit in Small Patient
Cohorts" Treatment and prognosis in AML is
strongly influenced by a patients age, and their
cytogenetic profile. In the majority of cases
these two prognostic influences are linked, with
a higher frequency of unfavorable cytogenetic
abnormalities observed in the elderly. Survival
in this cohort of elderly patients is very poor,
with a five year overall survival of 38 (Luger,
2010). Get Full Details On http//www.researchb
eam.com/acute-myeloid-leukemia-therapeutics-to-202
0-novel-therapies-to-offer-clinical-benefit-in-sma
ll-patient-cohorts-market
3
.
Report Overview
Despite a relatively advanced understanding of
genetic abnormalities associated with AML, the
introduction of targeted therapies is lagging in
this indication in comparison to other cancers
such as breast and lung cancer, with no approved
targeted therapies. Such slow development may be
a reflection of AMLs status as an orphan
indication. Intensive treatment in eligible
patients (younger patients, and approximately 50
of diagnosed elderly patients) is typically the
combination of the two chemotherapeutic agents
cytarabine and daunorubicin, both of which were
approved in the 1960s. In patients ineligible for
intensive first-line chemotherapy, options are
very poor, with the more recently approved Vidaza
and Dacogen as the treatment options, which both
offer unsatisfactory survival. Across all newly
diagnosed patients that obtain complete
remission, a stem cell transplant offers the
highest chance of long-term survival. However,
this procedure is risky, with a higher rate of
treatment related mortality in the absence of
better techniques to reduce the risk of
graft-versus-host disease.  The majority of
patients experience disease relapse, which is
almost always fatal. Treatment options in these
patients typically involve the off-label use of
chemotherapeutic agents, whether in combination
or as monotherapies.
4
.
Report Overview
There are clear gaps in the market for therapies
to meet several unmet needs by increasing the
initial length of remission improving treatment
options for newly-diagnosed patients, ineligible
for relapsed disease treatments improving the
success of and reducing the side effects of stem
cell transplantation and improving survival,
safety and quality of life in patients with
relapsed disease. The current developmental
pipeline addresses these gaps in the market,
along with the significant lack of targeted
therapies. Five of the eight pipeline products
are under development as non-intensive therapies
for the elderly, and six of the eight products
are being investigated in relapsed
disease.   Results so far have been mixed, with
several drugs offering no overwhelming clinical
benefit in Phase I and II clinical trials. Some
drugs have demonstrated encouraging results
namely CPX-351, quizartinib, StemEx, treosulfan
and midostaurin. All of these drugs are forecast
to be approved within the forecast period, a
result of clinical trial data that suggest these
drugs can offer improved survival in comparison
to the currently marketed products. It is
important to note however, that these
improvements and the subsequent approval of these
products is restricted to small patient cohorts
including patients with
5
Report Overview
secondary AML, those with internal tandem repeats
in Fms-like tyrosine kinase, and patients
eligible for a stem cell transplant, but for whom
a matched donor cannot be found. This
fragmentation in the treatment algorithm is a
reflection of the heterogeneity of AML, with
continued fractionation likely to be essential
for further effective treatments to be developed.
This is reflected in the current developmental
pipeline, with drugs targeting a high variety of
molecule types and molecular targets currently
under investigation in this disease. The small
patient cohorts the pipeline drugs are expected
to be approved in will result in each having a
minimal effect on any growth in market revenues
over the forecast period. They will nevertheless
stimulate market growth. An increase in
prevalence and treatment populations, driven by
aging populations across each territory will also
have a positive effect on market revenues.
However, as an orphan indication, the effect of
population growth is also expected to have a
minor effect. As a result, the global market
revenues are forecast to rise at a limited CAGR
of 4.8 from 632.4m in 2013 to 878.2m in
2020.  
6
Report Overview

• Scope
•  
• The report analyzes treatment usage patterns,
  marketed and pipeline drugs, and market forecasts
  across indications for AML.The report covers and
  includes -
• - A brief introduction to AML, including the
  diseases pathogenesis, risk factors and
  diagnosis
• - An in-depth analysis of the drug combinations
  used in the treatment of AML, including analyses
  of their safety, efficacy, and place in the
  disease treatment algorithm. This includes a heat
  map comparing the drug combinations in terms of
  safety and efficacy
• - A comprehensive review of the pipeline for AML
  therapies, including individual analysis of a
  number of late-stage pipeline drugs that have the
  potential to enter the market during the forecast
  period. The pipeline is analyzed on the basis of
  Phase distribution, molecule types and molecular
  targets, as well as administration routes
• - An additional in-depth analysis of pipeline
  drug clinical trials by phase, trial size, trial
  duration and program failure rate analyses for
  each molecule type and molecular target

7
Table of Contents
- A multi-scenario forecast data for the market
to 2020, taking into account how it will be
affected by the introduction of new drugs, the
expiry of key patents on current drugs and the
changes in disease epidemiology across the key
developed markets including the US, Canada,
Japan, Germany, the UK, France, Italy and Spain -
A discussion of the drivers and barriers for
market growth - An in-depth analysis of licensing
and co-development deals involving drugs
indicated in AML, including an in-depth outline
of the key deals Reasons to buy The report will
assist business development and enable marketing
executives to strategize their product launches,
by allowing them to - - Understand the efficacy
and safety of the current monotherapies and drug
combinations used in the treatment of AML, with
in-depth analysis of the disease treatment
algorithm - Understand the key signaling pathways
and molecular targets currently under
investigation in drug development for AML
8
Table of Contents
- Understand the vast scope of the pipeline,
including which molecule types and molecular
targets are most prominent - Observe the trends
in clinical trial duration and size by clinical
phase and molecule type, and use the clinical
trial failure rate analysis to assess the risk
profiles of current and/or future developmental
programs for AML cancer therapeutics - Assess the
potential clinical and commercial impact of
current late-stage pipeline molecules in the AML
therapeutics market - Assess the location of
involved companies, and the value of both
licensing and co-development deals involving
drugs under investigation for the treatment of
AML Enquiry about this report _at_
http//www.researchbeam.com/acute-myeloid-leukemia
-therapeutics-to-2020-novel-therapies-to-offer-cli
nical-benefit-in-small-patient-cohorts-market/enqu
ire-about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/acute-myeloid-leukemia
-therapeutics-to-2020-novel-therapies-to-offer-cli
nical-benefit-in-small-patient-cohorts-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com